Sana Biotechnology, Inc. announced encouraging preliminary results from a 12-week clinical study involving hypoimmune-modified pancreatic islet cells for type 1 diabetes, showing persistent C-peptide ...
ONS-5010 shows non-inferiority to Lucentis at 12 weeks; BLA resubmission planned for Q1 2025, with $20.4M in proceeds expected. ONS-5010 demonstrated non-inferiority to ranibizumab at week 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback